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Abstract
Background: Studies investigating the association between telomere length and diabetes have been inconsistent,
and there are few data available investigating the associations of telomere length with diabetes duration and
control. We evaluated the relationship of leukocyte telomere length with diabetes, and the relationship of leukocyte
telomere length with diabetes duration and poor glucose control among people with diabetes.
Methods: We used data from the 1999–2002 National Health and Nutrition Examination Survey, a representative
sample of the US civilian non-institutionalized population. In 3921 participants, leukocyte telomere length was
measured and diabetes status was determined based on a previous diagnosis, hemoglobin A1c ≥6.5 %, or fasting
glucose ≥126 mg/dL.
Results: The odds ratios (95 % confidence intervals) of diabetes associated with the first, second, and third quartile of
leukocyte telomere length, compared to the highest quartile, was 2.09 (1.46–2.98), 1.74 (1.30–2.31), and 1.08 (0.76–1.54),
respectively (p-trend < 0.01), in unadjusted models and 0.74 (0.48–1.14), 0.91 (0.61–1.34), and 0.87 (0.59–1.29),
respectively (p-trend = 0.20), in multivariable adjusted models. Among participants with diabetes, unadjusted and
adjusted leukocyte telomere length was not associated with diabetes duration or glucose control based on an
hemoglobin A1c <7 or <8 % (all p > 0.05).
Conclusions: In this study of the US general population, leukocyte telomere length was not associated with diabetes
status, diabetes duration, or diabetes control.
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Background
Telomeres are DNA protein structures at the end of all
chromosomes consisting of tandem repeats of TTAGGG
sequence [1]. They preserve the chromosomes’ stability
and integrity by overcoming the problem of DNA poly-
merase’s inability to fully copy the very end of the lag-
ging strand. The resulting telomere shortening is a sign
of physiologic aging and eventually leads to cell senes-
cence. A faster rate of attrition and consequently prema-
ture cell senescence may be a cause or a consequence of
type 2 diabetes [2]. Shorter telomeres leading to senes-
cence and apoptosis of the beta cells may contribute to
more rapid development of type 2 diabetes. Also, diabetes
and obesity are associated with increased oxidative stress,
which may in turn lead to telomere shortening [2, 3]. Sev-
eral previous studies have investigated the association be-
tween leukocyte telomere length (LTL) and diabetes with
inconsistent results [4–10]. This association has not been
studied in a representative sample of the US general popu-
lation. Furthermore, few data are available investigating the
association of LTL with diabetes duration or control [7].
We evaluated the relationship of LTL and diabetes
using data from the 1999–2002 National Health and Nu-
trition Examination Surveys (NHANES), a representative
sample of the US civilian non-institutionalized popula-
tion. In addition, we evaluated the relationship between
LTL and poor glucose control and diabetes duration
among people with diabetes.
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We limited our analysis to the years 1999–2002 because
those were the only years NHANES measured LTL.
NHANES 1999–2002 is a stratified, multistage probability
survey designed to be representative of the civilian, non-
institutionalized US population [11]. The de-identified
datasets are publicly available at http://www.cdc.gov/nchs/
nhanes/nhanes_questionnaires.htm. For the examination
portion of the survey, participants were randomly allo-
cated to either a morning examination for which they are
asked to fast (8 to <24 h) or an afternoon/evening examin-
ation. We used data from the morning examination ses-
sion in order to include fasting glucose in the definition of
diabetes; the morning examination data is capable of
independently producing national estimates. Of 4798
adults ≥20 years of age, we excluded three participants
with likely type 1 diabetes (diagnosis <30 years of age and
initiation of insulin within 1 year of diagnosis), 233 preg-
nant women, and 641 participants missing telomere data,
resulting in a final sample of 3921 participants.
The protocol for the 1999–2002 NHANES was ap-
proved by the National Center for Health Statistics
(NCHS) of the Centers for Disease Control and Preven-
tion research ethics board. All participants gave written
informed consent.
Data collection
Data for NHANES 1999–2002 were collected during an
in-home interview and a subsequent visit to a mobile
examination center (MEC) [11]. Standardized question-
naires were used to collect information regarding age,
race-ethnicity, sex, education, household income, smok-
ing status, pack years smoked, and alcohol consumption
during the in-home interview. During the examination,
height and weight were measured and body mass index
(BMI; weight [kg]/height [m2]) was calculated. A trained
phlebotomist obtained a blood sample according to a
standardized protocol and serum C-reactive protein
(CRP) was measured using latex-enhanced nephelome-
try, a high sensitivity assay.
Participants self-reported a previous diagnosis of diabetes
by a doctor or other health professional. Hemoglobin A1c
(A1c), a measure of average glucose levels over the past
three months, was measured in whole blood using a Pri-
mus Automated HPLC system (Primus Corp., Kansas City,
MO) and the interassay coefficient of variation ranged
from 1.1 to 2.0 %. Fasting plasma glucose was measured
using a Roche Cobas Mira Chemistry System (Roche Diag-
nostics Systems, Inc., Montclair, New Jersey) and the inter-
assay coefficient of variation ranged from 1.3 to
3.0 %. We defined diabetes as a previous diagnosis of
diabetes, A1c ≥6.5 % (48 mmol/mol), or fasting glu-
cose ≥126 mg/dL [12].
Aliquots of DNA purified from whole blood were pro-
vided by the Division of Health and Nutrition Examin-
ation Surveys, National Center for Health Statistics,
Centers for Disease Control and Prevention [13]. The la-
boratory of Elizabeth Blackburn at the University of
California, San Francisco performed the LTL assay using
the quantitative polymerase chain reaction method to
measure LTL relative to a reference DNA (T/S ratio)
[14, 15]. Each sample was assayed twice and if the vari-
ability was >7 %, then a third assay was run. The two
closest T/S ratio values were used to calculate an aver-
age. The interassay coefficient of variation was 4.4 %.
Statistical methods
LTL were categorized into quartiles based on the weighted
sample distribution of LTL. We calculated means (stand-
ard errors) and percentages (standard errors) of partici-
pant characteristics by quartile of LTL. We used logistic
regression to estimate the odds ratios and 95 % confidence
intervals of diabetes associated with each quartile of LTL.
We tested for linear trends across quartiles of LTL by in-
cluding the median LTL value for each quartile as a con-
tinuous variable in logistic regression models. Initial
regression models were unadjusted; a subsequent model
was adjusted for age, race-ethnicity, and sex, while a final
multivariable model adjusted for age, race-ethnicity, sex,
education, income, smoking, pack years smoked, alcohol
consumption, body mass index, and C-reactive protein.
We also calculated the geometric mean LTL by dia-
betes status (normal glucose level/prediabetes/diabetes),
duration of diabetes among people with diabetes (un-
diagnosed/diagnosed with duration < 3 years/3–5 years/
6–10 years/≥11 years), and A1c control among people
with diagnosed diabetes (using 7 % [53 mmol/mol] and
8 % [64 mmol/mol] cutpoints based on American Dia-
betes Association treatment goals) [16]. To do so, we
calculated conditional margins (essentially adjusted mean
values of the dependent variable for each category of an
independent variable) [17] from linear regression models
with LTL modeled as a continuous, log-transformed vari-
able using adjustment identical to the models described
above. P-values for differences in geometric mean LTL by
diabetes status, duration, and control were calculated
using Wald F-tests.
Appropriate sample weights were used in all analyses so
that the sum of the sample weights (MEC and fasting
weights) added to the total civilian non-institutionalized
US population; weights were used to account for unequal
probabilities of selection and non-response and thus pro-
vide estimates representative of the non-institutionalized
US population. Data analyses were done using SUDAAN
(version 10.0.1; RTI International, Research Triangle Park,
NC) accounting for the stratified, clustered sample design
used by NHANES.
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Results
Participants in lower quartiles of LTL were older, more
likely to be non-Hispanic white, less likely to be non-
Hispanic black, and less likely to be women compared to
their counterparts in higher LTL quartiles (p-trend <0.05
for all; Table 1). They were less likely to have a high
school education or to be never smokers; they had
higher mean pack years smoked (among smokers), body
mass index, and A1c levels; and they were more likely
to have C-reactive protein ≥1.0 mg/dL and diabetes
(p-trend <0.05 for all).
The unadjusted odds ratios and 95 % confidence inter-
vals (95 % CI) of diabetes associated with the first, sec-
ond, and third quartile of LTL, compared to the highest
quartile, was 2.09 (95 % CI, 1.46–2.98), 1.74 (95 % CI,
1.30–2.31), and 1.08 (95 % CI, 0.76–1.54), respectively
(p-trend < 0.01; Table 2). After multivariable adjustment,
the analogous estimates were 0.74 (95 % CI, 0.48–1.14),
0.91 (95 % CI, 0.61–1.34), and 0.87 (95 % CI, 0.59–1.29),
respectively (p-trend = 0.20).
Geometric mean LTL was not associated with diabetes
status, duration of diabetes, or control of diabetes after
age, race-ethnicity, and sex adjustment or multivariable
adjustment (Table 3). In multivariable adjusted models,
the geometric mean LTL was 1.000 (95 % CI, 0.967–
1.034) for normal glucose levels, 1.009 (95 % CI, 0.970–
1.050) for prediabetes, and 1.032 (95 % CI, 0.996–1.069)
for diabetes (p = 0.11). Among participants with diabetes,
the multivariable adjusted geometric mean LTL was
0.957 (95 % CI, 0.921–0.994) for undiagnosed diabetes,
0.983 (95 % CI, 0.917–1.055) for 0–2 years duration,
0.971 (95 % CI, 0.909–1.037) for 3–5 years duration,
0.974 (95 % CI, 0.904–1.050) for 6–10 years duration,
and 0.989 (95 % CI, 0.940–1.041) for ≥11 years duration
(p = 0.57). Among participants with diagnosed diabetes,
the multivariable geometric mean LTL was 0.955 (95 %
CI, 0.911–1.001) for A1c <7 % and 0.939 (95 % CI,
0.904–0.976) for A1c ≥7 % (p = 0.43).
Discussion
In this large, population based study of the US general
population, lower LTL was associated with higher preva-
lence of diabetes in unadjusted models. However, in
models adjusted for age, race-ethnicity, and sex and in
multivariable adjusted models, the association between
LTL and diabetes was attenuated and no longer significant.
In addition, LTL was not associated with diabetes duration
or diabetes control in unadjusted or adjusted models.
Previous studies investigating the association between
diabetes status and LTL have been inconsistent. In a
Table 1 Characteristicsa of participants by quartile of leukocyte telomere lengthb, 1999–2002
LTL LTL LTL LTL
<0.87 0.87–1.01 1.02–1.19 ≥1.20 p-trend
Age, years 55.4 (0.7) 48.5 (1.1) 42.4 (1.0) 37.9 (1.0) <0.01
Non-Hispanic white, % 77.9 (3.1) 75.9 (2.5) 72.7 (2.9) 66.7 (2.9) <0.01
Non-Hispanic black, % 7.7 (1.2) 8.6 (1.6) 8.7 (1.3) 13.2 (2.3) 0.01
Mexican-American, % 6.0 (1.3) 7.1 (1.2) 7.9 (1.2) 6.5 (1.2) 0.76
Women, % 45.3 (1.6) 53.0 (2.1) 51.2 (2.3) 51.7 (2.1) 0.04
<High school education, % 26.7 (1.4) 21.4 (1.5) 19.9 (1.8) 18.0 (1.6) <0.01
High school education, % 25.3 (1.9) 28.9 (2.5) 25.6 (2.3) 27.6 (2.4) 0.67
>High school education, % 47.9 (2.0) 49.7 (2.6) 54.4 (2.7) 54.4 (2.7) 0.03
Household income < $20,000, % 26.5 (1.7) 21.2 (1.6) 21.9 (2.3) 26.8 (3.0) 0.81
Current smokers, % 22.1 (1.6) 26.1 (2.3) 24.6 (2.3) 26.6 (2.4) 0.22
Former smokers, % 32.9 (1.7) 28.6 (2.4) 23.4 (1.8) 21.1 (1.9) <0.01
Never smokers, % 45.1 (2.0) 45.4 (1.8) 52.0 (2.4) 52.3 (3.1) <0.01
Pack years smoked, mean years 29.5 (1.6) 25.2 (1.1) 19.5 (1.1) 14.5 (1.2) <0.01
Consume alcohol, % 68.9 (1.6) 73.7 (2.9) 74.1 (3.1) 76.0 (3.4) 0.10
Body mass index, kg/m2 28.6 (0.3) 28.4 (0.3) 27.6 (0.3) 27.4 (0.3) <0.01
C-reactive protein ≥1 mg/dL, % 12.9 (1.3) 10.1 (1.0) 7.8 (1.0) 8.7 (1.3) 0.04
Diabetes, % 12.9 (0.8) 11.0 (0.9) 7.1 (0.8) 6.6 (0.8) <0.01
A1c, mean % 5.6 (0.03) 5.5 (0.03) 5.4 (0.03) 5.3 (0.03) <0.01
A1c, mean mmol/mol 34 (0.3) 37 (0.3) 36 (0.3) 34 (0.3) <0.01
LTL leukocyte telomere length
aMean (standard error) or percentage (standard error)
bTelomere length was measured relative to standard reference DNA and presented as a ratio (T/S ratio)
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cross-sectional study and in three case–control studies,
participants with diabetes had shorter LTL than those
without diabetes [5–7, 9]. In the Strong Heart Study, a
prospective cohort study of participants without diabetes
at baseline, those in the lowest quartile of LTL had an
83 % higher risk of developing diabetes after 5.5 years of
follow-up than those in the highest quartile of LTL [10].
Among participants of the Finnish Diabetes Prevention
Study with impaired glucose tolerance, baseline LTL was
not associated with the development of diabetes after
8.5 years of follow-up [4]. In a nested case–control study
including postmenopausal women participating in the
Women’s Health Initiative, baseline LTL were similar
among women who developed diabetes and those who did
not develop diabetes after 6 years of follow-up; this study
also found no association between telomere length and
diabetes risk in a Mendelian randomization analysis [8].
Since diabetes and obesity are associated with greater
oxidative stress, the conditions may also cause more
rapid LTL shortening [2], and consequently those with a
longer diabetes duration and poor glucose control may
experience faster LTL attrition. However, we found no
evidence of an association in our study. We were only
able to identify one previous study investigating the as-
sociation between duration of diabetes and LTL, and it
found no association [7]. Among people with diabetes,
LTL may be related to complications, as previous studies
in diabetes populations have found that LTL was associ-
ated with renal disease [18, 19].
Our study had a number of strengths, including use of a
rigorous study protocol with extensive quality control pro-
cedures and technicians trained and certified in all data
collection procedures. The sample size was large with a
sufficient number of diabetic participants to investigate
Table 2 Odds ratios (95 % confidence intervals) of diabetes associated with quartile of leukocyte telomere lengtha, 1999–2002
LTL LTL LTL LTL
<0.87 0.87–1.01 1.02–1.19 ≥1.20 p-trend
Unadjusted 2.09 (1.46–2.98) 1.74 (1.30–2.31) 1.08 (0.76–1.54) 1.00 <0.01
Age, race-ethnicity, and sex adjusted 0.89 (0.63–1.26) 1.08 (0.80–1.47) 0.86 (0.62–1.19) 1.00 0.73
Multivariable adjustedb 0.74 (0.48–1.14) 0.91 (0.61–1.34) 0.87 (0.59–1.29) 1.00 0.20
LTL leukocyte telomere length
aTelomere length was measured relative to standard reference DNA and presented as a ratio (T/S ratio)
bMultivariable model adjusted for age, race-ethnicity, sex, education, income, smoking, pack years smoked, alcohol consumption, body mass index, and
C-reactive protein
Table 3 Geometric mean (95 % confidence interval) leukocyte telomere lengtha by diabetes status, diabetes control, and diabetes
duration, 1999–2002
Unadjusted Age, race-ethnicity, and sex adjusted Multivariable adjustedb
Diabetes status p < 0.01 p = 0.68 p = 0.11
Normal 1.045 (1.010–1.082) 1.012 (0.979–1.046) 1.000 (0.967–1.034)
Prediabetes 0.970 (0.937–1.006) 1.010 (0.974–1.048) 1.009 (0.970–1.050)
Diabetes 0.946 (0.918–0.974) 1.020 (0.989–1.053) 1.032 (0.996–1.069)
Duration among those with diabetes p = 0.44 p = 0.90 p = 0.57
Undiagnosed 0.970 (0.937–1.006) 0.965 (0.932–0.999) 0.957 (0.921–0.994)
Duration 0–2 years 0.977 (0.916–1.041) 0.966 (0.901–1.035) 0.983 (0.917–1.055)
Duration 3–5 years 0.969 (0.920–1.022) 0.984 (0.938–1.032) 0.971 (0.909–1.037)
Duration 6–10 years 0.950 (0.889–1.015) 0.974 (0.918–1.033) 0.974 (0.904–1.050)
Duration ≥11 years 0.927 (0.884–0.972) 0.982 (0.938–1.028) 0.989 (0.940–1.041)
Control among diagnosed diabetes (7 %) p = 0.43 p = 0.65 p = 0.43
A1c <7 % (53 mmol/mol) 0.943 (0.909–0.978) 0.954 (0.918–0.992) 0.955 (0.911–1.001)
A1c ≥7 % (53 mmol/mol) 0.956 (0.920–0.993) 0.947 (0.913–0.982) 0.939 (0.904–0.976)
Control among diagnosed diabetes (8 %) p = 0.80 p = 0.12 p = 0.20
A1c <8 % (64 mmol/mol) 0.948 (0.915–0.983) 0.961 (0.927–0.997) 0.957 (0.918–0.999)
A1c ≥8 % (64 mmol/mol) 0.953 (0.912–0.997) 0.930 (0.891–0.971) 0.926 (0.882–0.973)
aTelomere length was measured relative to standard reference DNA and presented as a ratio (T/S ratio)
bMultivariable model adjusted for age, race-ethnicity, sex, education, income, smoking, pack years smoked, alcohol consumption, body mass index, and
C-reactive protein
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the associations of diabetes duration and control with
LTL. Also, the results of NHANES are generalizable to the
civilian, noninstitutionalized US population. However, the
study had limitations, including a cross-sectional study de-
sign with LTL measured from a single DNA specimen;
therefore, we did not have data on the rate of LTL short-
ening. Telomere length may vary among cells in the same
tissue and among chromosomes in the same cell, but a
previous study showed telomere length from different tis-
sues within the same person are highly correlated [20].
Conclusions
In conclusion, we did not find an association between
LTL and diabetes status, duration, or control after ad-
justment. Our results suggest telomere attrition is not a
cause or a consequence of diabetes.
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